Recruitment Details

Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details

Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups

	Description
Truvada	Truvada + nonnucleoside reverse transcriptase inhibitor (NNRTI) or protease inhibitor (PI).
Zidovudine/Lamivudine	Zidovudine/lamivudine + nonnucleoside reverse transcriptase inhibitor (NNRTI) or protease inhibitor (PI).

Participant Flow:   Overall Study

	Truvada	Zidovudine/Lamivudine
STARTED	39	41
COMPLETED	37	36
NOT COMPLETED	2	5
Adverse Event	1	4
Withdrawal by Subject	0	1
Noncompliance	1	0

1.  Primary:

Change From Baseline in Limb Fat at Week 48   [ Baseline to Week 48 ]

2.  Secondary:

Change From Baseline in the Mitochondrial DNA/Nuclear DNA Ratio (Oral Mucosa)   [ Baseline to Week 48 ]

3.  Secondary:

Change From Baseline in the Mitochondrial DNA/Nuclear DNA Ratio (Lymphocytes)   [ Baseline to Week 48 ]

4.  Secondary:

Change From Baseline in Lactate Concentration   [ Baseline to Week 48 ]

5.  Secondary:

Percentage of Days for Which Participants Were Compliant With Study Drug   [ Baseline to Week 72 ]

6.  Secondary:

Percentage of Participants Who Maintain Confirmed HIV-1 RNA < 50 Copies/mL   [ 48 weeks ]

7.  Secondary:

Percentage of Participants With HIV-1 RNA > 50 and < 400 Copies/mL   [ 48 weeks ]

8.  Secondary:

Percentage of Participants With Virologic Failure   [ 48 weeks ]

9.  Secondary:

Change From Baseline in Cluster Determinant 4 (CD4) Cell Count   [ Baseline to Week 48 ]

10.  Secondary:

Change From Baseline in Fasting Serum Triglycerides   [ Baseline to Week 48 ]

11.  Secondary:

Change From Baseline in Fasting Total Cholesterol   [ Baseline to Week 48 ]

12.  Secondary:

Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL)   [ Baseline to Week 48 ]

13.  Secondary:

Change From Baseline in Fasting High Density Lipoprotein Cholesterol (HDL)   [ Baseline to Week 48 ]

14.  Secondary:

Change From Baseline in Hemoglobin   [ Baseline to Week 48 ]

15.  Secondary:

Change From Baseline in Hematocrit   [ Baseline to Week 48 ]

16.  Secondary:

Change From Baseline in Waist Circumference/Hip Circumference Ratio   [ Baseline to Week 48 ]

17.  Secondary:

Percentage of Participants With Any Adverse Event   [ 72 weeks ]

18.  Secondary:

Percentage of Participants Who Discontinue the Study Prematurely (Before Week 48) Due to Adverse Events.   [ 48 weeks ]